Organization | Jaeb Center for Health Research

Jaeb Center for Health Research Report issue

Foundation Phase 1 Phase 2 Phase 3 Phase 4

Founded: Tampa FL United States (1993)

Organization Overview

First Clinical Trial

1999

NCT00000170

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Jaeb Center for Health Research

Active Ingredients

Drugs in Phase 4 Trials (3)

atropine (8 trials)

insulin degludec (tresiba) (1 trial)

insulin human (humulin) (4 trials)

Drugs in Phase 3 Trials (14)

acetazolamide (diamox) (1 trial)

aflibercept (zaltrap) (5 trials)

bevacizumab (avastin) (6 trials)

carbidopa (sinemet) (2 trials)

faricimab (Vabysmo) (1 trial)

fenofibrate (fenoglide) (1 trial)

glucagon (4 trials)

levodopa (larodopa) (2 trials)

pemafibrate (1 trial)

ranibizumab (lucentis) (6 trials)

sitagliptin (januvia) (2 trials)

sodium chloride (1 trial)

triamcinolone (kenalog) (4 trials)

verapamil (calan) (1 trial)

Drugs in Phase 2 Trials (3)

glucose (2 trials)

nepafenac (nevanac) (1 trial)

Drugs in Phase 1 Trials (1)

terbutaline (bricanyl) (1 trial)

Drugs in Other Trials (2)

insulin aspart (Novolog) (1 trial)

insulin lispro (humalog) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Amblyopia (Phase 4)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 1 (Phase 3)

Diabetic Retinopathy (Phase 3)

Edema (Phase 3)

Hemorrhage (Phase 3)

Hypertension (Phase 3)

Hypoglycemia (Phase 3)

Insulin Resistance (Phase 3)

Intracranial Hypertension (Phase 3)

Macular Edema (Phase 3)

Myopia (Phase 3)

Overweight (Phase 3)

Premature Birth (Phase 3)

Pseudotumor Cerebri (Phase 3)

Retinal Diseases (Phase 3)

Retinopathy of Prematurity (Phase 3)

Vitreous Hemorrhage (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 42
# of Trial APIs: 23